Chepstow-based biotech company Creo Medical to list on AIM
“Creo Medical is the fourth Finance Wales portfolio company to
list on AIM in the last four years. Our initial investment in 2012
led them to relocate their headquarters and product development
facility to Chepstow. We’ve since supported them over multiple
rounds of equity investment and leveraged significant private and
corporate co-investment in the process. It’s exciting to see yet
another Welsh life science company list after support from our
Technology Venture Investments team. Raising £20 million in their
debut on AIM will allow them to complete key product development
programmes, secure regulatory approvals and drive early sales in
Europe and the US.
“We’re an active technology investor, offering debt and equity
investments to a range of technology-focused businesses in the
SAAS, Artificial Intelligence, data analytics, med tech, clean tech
and advanced materials sectors. Through our Technology Seed Fund
and later stage Technology Venture funds, we are able to support
businesses from start up, through commercial growth to eventual
“As well as supporting indigenous businesses Finance Wales - in
partnership with Welsh Government - targets high calibre technology
businesses willing to relocate to Wales to benefit our seed and
“Our dedicated Technology Venture Investments team have invested
nearly £8 million already since April this year, leveraging
significant private sector co-investment.”
Steve Smith, Director,
Technology Venture Investments, Finance Wales
“We’ve been investing in Creo Medical since 2012 – investing
more than £3 million over multiple funding rounds – with an
additional £1.9 million being invested at IPO. This has been done
in collaboration with extensive co-investment from a brilliant
group of angel investors and most recently Japanese corporate Hoya
Group Pentax Medical.
“Creo’s innovative technology has real benefit to the medical
community and is supported by an award-winning management team.
They are an emerging med-tech leader and its CROMA electrosurgical
platform is ground breaking and has significant potential to
improve the outcomes of a range of medical procedures. It has
always been a pleasure to work with Craig and the Creo team. We
wish them every success in building Creo into a very significant
med-tech listed company.”
Dr Richard Thompson, Senior
Investment Executive, Finance Wales
- AIM is a submarket of the London Stock Exchange and was
launched in 1995.
- Creo Medical is developing a range of surgical devices that can
dissect tissue while using special microwaves to staunch the blood
flow. The devices are designed to be used with an endoscope to
reduce the need for open surgery.
- Shares will begin trading on Friday, priced at 76p, giving Creo
a market capitalisation of £61.3m. They are seeking to raise £20
million with the listing.
- Previous Finance Wales portfolio companies to list on AIM
include Diurnal, Enfis, and Medaphor. Q-Chip also became
Midatech Pharma Wales when they were acquired by MidaTech with a
concurrent AIM listing.